|
|
Volumn 105 Suppl 2, Issue , 2012, Pages
|
|
Inhaled antibiotics in cystic fibrosis: what's new?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMIKACIN;
ANTIINFECTIVE AGENT;
AZTREONAM;
CIPROFLOXACIN;
TOBRAMYCIN;
ADOLESCENT;
CHILD;
COMPARATIVE STUDY;
CYSTIC FIBROSIS;
FEMALE;
FOLLOW UP;
GRAM NEGATIVE INFECTION;
GRAM POSITIVE INFECTION;
HOSPITALIZATION;
HUMAN;
INCIDENCE;
INFANT;
INHALATIONAL DRUG ADMINISTRATION;
MALE;
MICROBIOLOGY;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRESCHOOL CHILD;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
REVIEW;
RISK ASSESSMENT;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADMINISTRATION, INHALATION;
ADOLESCENT;
AMIKACIN;
ANTI-BACTERIAL AGENTS;
AZTREONAM;
CHILD;
CHILD, PRESCHOOL;
CIPROFLOXACIN;
CLINICAL TRIALS, PHASE III AS TOPIC;
CYSTIC FIBROSIS;
FEMALE;
FOLLOW-UP STUDIES;
GRAM-NEGATIVE BACTERIAL INFECTIONS;
GRAM-POSITIVE BACTERIAL INFECTIONS;
HUMANS;
INCIDENCE;
INFANT;
MALE;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
SEVERITY OF ILLNESS INDEX;
SURVIVAL RATE;
TOBRAMYCIN;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 84865299999
PISSN: None
EISSN: 17581095
Source Type: Journal
DOI: 10.1258/jrsm.2012.12s004 Document Type: Review |
|
Times cited : (18)
|
|
References (0)
|
